Drug Profile
Nefiracetam
Alternative Names: BRN 6848330; CCRIS 6729; DM 9384; DMPPA; DN-9384; DZL-221; HL-0812; HPI-001; Motiva; TranslonLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Neuren Pharmaceuticals
- Class Acetamides; Neuroprotectants; Nootropics; Pyrrolidinones; Small molecules
- Mechanism of Action Calcium channel agonists; GABA receptor agonists; Nicotinic receptor agonists; NMDA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
- Discontinued Dementia; Major depressive disorder
Most Recent Events
- 15 Mar 2011 Phase-II development is ongoing in US, Australia and Canada for Depression in post-stroke patients
- 08 Jun 2010 Clinical development is ongoing
- 12 Mar 2008 Phase-II clinical trials in Depression in USA (PO)